Stock listing
Hamburg:5DT Entera Bio Ltd. Aktie
German listing (Hamburg) of Entera Bio Ltd. · home listing NASDAQ:ENTX
Follow Entera Bio Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ENTX
$3.31 USD +0.05 (+1.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ENTX
- Day range
- $3.18 – $3.33 USDNov 20, 2026
- Volume
- 469,047 sharesNov 20, 2026
- Market cap
- $574.8M USDAt the close on Nov 20, 2026 · price × 173.9M shares outstanding
- 52-week range
- $0.91 – $4.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.28M USDMedian day 329,883 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ENTX · Home | $3.305 USD | +0.045 (+1.4%) | 469,047 | $3.25 | $3.33 | $3.175 | $3.26 | Close on Nov 20, 2026 |
| Frankfurt:5DT | €2.88 EUR | 0.00 (0.0%) | — | €2.88 | €2.88 | €2.88 | €2.88 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.305 | +0.045 | +1.4% | $3.25 | $3.33 | $3.175 | 469,047 | |
| $3.26 | +0.26 | +8.7% | $3.03 | $3.27 | $3.00 | 493,477 | |
| $3.00 | -0.02 | -0.7% | $3.05 | $3.10 | $3.00 | 187,391 | |
| $3.02 | -0.09 | -2.9% | $3.11 | $3.117 | $3.00 | 208,609 | |
| $3.11 | -0.11 | -3.4% | $3.22 | $3.265 | $3.08 | 155,334 | |
| $3.22 | 0.00 | 0.0% | $3.20 | $3.24 | $3.13 | 170,483 | |
| $3.22 | -0.02 | -0.6% | $3.275 | $3.275 | $3.13 | 103,427 | |
| $3.24 | -0.01 | -0.3% | $3.25 | $3.25 | $3.17 | 98,553 | |
| $3.25 | +0.11 | +3.5% | $3.17 | $3.488 | $3.11 | 512,162 | |
| $3.14 | +0.15 | +5.0% | $3.03 | $3.18 | $2.91 | 118,328 | |
| $2.99 | -0.12 | -3.9% | $3.07 | $3.10 | $2.90 | 219,761 | |
| $3.11 | +0.06 | +2.0% | $3.05 | $3.20 | $3.05 | 291,239 | |
| $3.05 | -0.04 | -1.3% | $3.06 | $3.12 | $2.99 | 136,933 | |
| $3.09 | -0.11 | -3.4% | $3.19 | $3.29 | $2.99 | 329,883 | |
| $3.20 | +0.08 | +2.6% | $3.06 | $3.24 | $2.95 | 292,681 | |
| $3.12 | +0.02 | +0.6% | $3.08 | $3.189 | $3.01 | 140,950 | |
| $3.10 | +0.04 | +1.3% | $3.05 | $3.195 | $3.005 | 181,559 | |
| $3.06 | +0.20 | +7.0% | $2.85 | $3.13 | $2.81 | 203,525 | |
| $2.86 | -0.06 | -2.1% | $2.90 | $2.90 | $2.80 | 232,466 | |
| $2.92 | -0.10 | -3.3% | $2.99 | $3.02 | $2.86 | 256,927 | |
| $3.02 | -0.03 | -1.0% | $3.01 | $3.04 | $2.901 | 629,476 | |
| $3.05 | +0.03 | +1.0% | $3.12 | $3.20 | $2.96 | 784,597 | |
| $3.02 | +0.08 | +2.7% | $2.79 | $3.26 | $2.79 | 791,927 | |
| $2.94 | +0.26 | +9.7% | $2.66 | $2.97 | $2.62 | 953,139 | |
| $2.68 | -0.09 | -3.2% | $2.72 | $2.75 | $2.62 | 572,891 | |
| $2.77 | +0.27 | +10.8% | $2.49 | $2.82 | $2.49 | 1,447,906 | |
| $2.50 | +0.01 | +0.4% | $2.47 | $2.565 | $2.46 | 784,486 | |
| $2.49 | -0.16 | -6.0% | $2.65 | $2.65 | $2.435 | 755,300 | |
| $2.65 | -0.01 | -0.4% | $2.66 | $2.775 | $2.639 | 305,688 | |
| $2.66 | +0.16 | +6.4% | $2.51 | $2.72 | $2.505 | 1,584,092 | |
| $2.50 | -0.01 | -0.4% | $2.48 | $2.52 | $2.45 | 421,033 | |
| $2.51 | -0.02 | -0.8% | $2.52 | $2.58 | $2.45 | 679,477 | |
| $2.53 | -0.09 | -3.4% | $2.66 | $2.67 | $2.53 | 621,167 | |
| $2.62 | -0.24 | -8.4% | $2.89 | $2.89 | $2.62 | 1,254,986 | |
| $2.86 | -0.03 | -1.0% | $2.89 | $2.90 | $2.82 | 100,700 | |
| $2.89 | -0.02 | -0.7% | $2.89 | $3.00 | $2.81 | 640,880 | |
| $2.91 | +0.22 | +8.2% | $2.67 | $2.975 | $2.57 | 520,976 | |
| $2.69 | 0.00 | 0.0% | $2.70 | $2.72 | $2.66 | 160,845 | |
| $2.69 | -0.055 | -2.0% | $2.80 | $2.89 | $2.645 | 340,910 | |
| $2.745 | -0.055 | -2.0% | $2.91 | $2.91 | $2.70 | 776,301 | |
| $2.80 | -0.01 | -0.4% | $2.78 | $2.88 | $2.71 | 234,000 | |
| $2.81 | -0.17 | -5.7% | $3.01 | $3.01 | $2.70 | 858,157 | |
| $2.98 | +0.02 | +0.7% | $3.02 | $3.03 | $2.945 | 613,718 | |
| $2.96 | 0.00 | 0.0% | $2.93 | $2.97 | $2.86 | 294,685 | |
| $2.96 | -0.07 | -2.3% | $3.14 | $3.14 | $2.88 | 288,975 | |
| $3.03 | +0.07 | +2.4% | $2.95 | $3.05 | $2.94 | 310,173 | |
| $2.96 | +0.10 | +3.5% | $2.86 | $3.05 | $2.785 | 777,611 | |
| $2.86 | +0.04 | +1.4% | $2.77 | $2.86 | $2.68 | 391,364 | |
| $2.82 | -0.02 | -0.7% | $2.81 | $2.90 | $2.76 | 100,044 | |
| $2.84 | +0.05 | +1.8% | $2.85 | $2.94 | $2.825 | 187,608 | |
| $2.79 | -0.05 | -1.8% | $2.82 | $2.85 | $2.72 | 437,618 | |
| $2.84 | -0.17 | -5.6% | $2.99 | $3.04 | $2.83 | 622,167 | |
| $3.01 | +0.01 | +0.3% | $2.95 | $3.07 | $2.82 | 824,636 | |
| $3.00 | +0.05 | +1.7% | $2.95 | $3.15 | $2.88 | 606,922 | |
| $2.95 | +0.03 | +1.0% | $2.99 | $3.025 | $2.90 | 154,038 | |
| $2.92 | +0.02 | +0.7% | $2.90 | $3.00 | $2.84 | 143,497 | |
| $2.90 | -0.05 | -1.7% | $2.94 | $3.09 | $2.80 | 256,682 | |
| $2.95 | -0.08 | -2.6% | $3.03 | $3.09 | $2.915 | 214,454 | |
| $3.03 | -0.05 | -1.6% | $3.12 | $3.15 | $3.00 | 138,183 | |
| $3.08 | -0.11 | -3.4% | $3.20 | $3.41 | $3.03 | 240,676 | |
| $3.19 | -0.28 | -8.1% | $3.46 | $3.47 | $3.10 | 523,310 | |
| $3.47 | +0.05 | +1.5% | $3.42 | $3.56 | $3.405 | 429,970 | |
| $3.42 | +0.19 | +5.9% | $3.28 | $3.47 | $3.20 | 258,132 | |
| $3.23 | +0.01 | +0.3% | $3.22 | $3.34 | $3.14 | 441,300 | |
| $3.22 | +0.11 | +3.5% | $3.01 | $3.33 | $3.00 | 468,467 |
- Ticker
- Hamburg:5DT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 6, 2026
Entera Announces Third Quarter 2026 Financial Results and Business Updates
Latest news
Entera Announces Third Quarter 2026 Financial Results and Business Updates
Nov 6, 2026
Closed $3.25 (+3.5%) on Nov 9, 2026
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
Oct 27, 2026
Closed $3.06 (+7.0%) on Oct 27, 2026
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
Oct 13, 2026
Closed $2.49 (-6.0%) on Oct 13, 2026
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
Oct 8, 2026
Closed $2.50 (-0.4%) on Oct 8, 2026
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Oct 6, 2026
Closed $2.53 (-3.4%) on Oct 6, 2026
Correction: Entera to Participate in Upcoming Fall Investor Conferences
Aug 27, 2026
Closed $3.08 (-3.4%) on Aug 27, 2026
Entera to Participate in Upcoming Fall Investor Conferences
Aug 27, 2026
Closed $3.08 (-3.4%) on Aug 27, 2026
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Aug 18, 2026
Closed $2.89 (-0.3%) on Aug 18, 2026
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Aug 7, 2026
Closed $3.04 (+5.9%) on Aug 10, 2026
Entera Bio Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 30 in the last 12 months · 141 in all · newest Nov 6, 2026 · oldest 2019
- Calls
- 5 calls with a replay · 5 with a transcript · latest May 18, 2022
- Decks
- 10 decks · latest September 2025
Where Entera Bio Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ENTX · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2JQXP | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JQXP | Lang & Schwarz | Germany | EUR |
| Stuttgart:5DT | Stuttgart | Germany | EUR |
| BOATS:ENTX | BOATS | United States | USD |
| Tradegate:5DT | Tradegate | Germany | EUR |
| Dusseldorf:5DT | Dusseldorf | Germany | EUR |
| Frankfurt:5DT | Frankfurt | Germany | EUR |
| Hamburg:5DT · This page | Hamburg | Germany | EUR |
Valuation
Price/book 2.1× against a median of 2.3×: 6th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $308.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Entera Bio Ltd. · NASDAQ:ENTX | US$574.8M | US$308.9M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | 0.76 |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Design Therapeutics, Inc. · NASDAQ:DSGN | US$577.6M | US$371.5M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.29 |
| Cullinan Therapeutics, Inc. · NASDAQ:CGEM | US$577.1M | US$289.6M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 1.45 |
| Immix Biopharma, Inc. · NASDAQ:IMMX | US$577.0M | US$241.7M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.60 |
| DBV Technologies SA · EURONEXT:DBV | US$571.8M | US$430.7M | n/a | 47.1× | n/a | 3.9× | n/a | 0.1× | n/a |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.4M | US$231.6M | n/a | 761× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.8M | US$613.5M | 14.5× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| Median of the others | US$571.6M | US$330.5M | 14.5× | 47.1× | 22.9× | 2.3× | −90.3% | 0.0× | 1.45 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.42 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Miranda Toledano | Chief Executive Officer and Board Member |
| Dana-Garbeli Yaacov | Chief Financial Officer |
| Hillel Galitzer | Chief Operating Officer |
| Anke Hoppe | VP of Clinical Operations |
| Cherin Smith | SVP Clinical Operations |
| Michele McDermott | SVP Medical Affairs |
| Gregory Burshtein | Chief Scientific Officer |
| Michal Kushnir | Head of Program Management |
| Osnat Bar-Peled | Executive Director of IP |
| Rachel B. Wagman | Chief Clinical Advisor |
| Riccardo Paolo Camisasca | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Geno J. Germano | Chairman of the Board |
| Gerald Lieberman | Director |
| Gerald M. Ostrov | Board Member |
| Haya Taitel | Board Member |
| Miranda Toledano | Chief Executive Officer and Board Member |
| Sean Ellis | Board Member |
| Steve Rubin | |
| Yonatan Malca | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Entera Bio (NASDAQ:ENTX) Q1 2022 Earnings Call | Wed, May 18, 2022 · 8:00 AM ET | Replay |
| Entera Bio (NASDAQ:ENTX) Q4 2021 Earnings Call | Tue, Mar 08, 2022 · 8:30 AM ET | Replay |
| Entera Bio (NASDAQ:ENTX) Q2 2021 Earnings Call | Mon, Aug 16, 2021 · 8:30 AM ET | Replay |
| Entera Bio (NASDAQ:ENTX) Q1 2021 Earnings Call | Thu, May 20, 2021 · 8:30 AM ET | Replay |
| Entera Bio (NASDAQ:ENTX) Q4 2020 Earnings Call | Thu, Mar 18, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · After close | +3.5% |
| Q2 2026 | Aug 7, 2026 | +7.8% |
| Q1 2026 | May 8, 2026 · After close | −10.0% |
| Q4 2025 | Mar 27, 2026 | −2.9% |
| Q3 2025 | Nov 14, 2025 · After close | −1.1% |
| Q2 2025 | Aug 8, 2025 · After close | +3.3% |
| Q1 2025 | May 9, 2025 · After close | 0.0% |
| Q4 2024 | Mar 6, 2025 · Before open | −3.6% |
| Q3 2024 | Nov 8, 2024 · After close | −1.2% |
| Q2 2024 | Aug 9, 2024 · After close | −2.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | −4.9% |
| Q4 2023 | Mar 8, 2024 · After close | +5.0% |
| Q3 2023 | Nov 14, 2023 · Before open | +2.9% |
| Q2 2023 | Aug 11, 2023 · After close | −17.6% |
| Q1 2023 | May 5, 2023 · After close | +7.3% |
| Q4 2022 | Mar 31, 2023 · After close | −13.4% |
| Q3 2022 | Nov 10, 2022 · After close | −19.2% |
| Q2 2022 | Aug 11, 2022 · Before open | +1.6% |
| Q1 2022 | May 12, 2022 · Before open | +4.5% |
| Q4 2021 | Mar 8, 2022 · Before open | −4.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2025) | Technical | 19 slides | September 2025 |
| Technical Presentation (July 2025) | Technical | 14 slides | July 2025 |
| Investor Presentation (September 2023) | Investor deck | 36 slides | September 2023 |
| Investor Presentation (March 2023) | Investor deck | 33 slides | March 2023 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | November 2022 |
| Investor Presentation (November 2022) | Investor deck | 35 slides | November 2022 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | November 2022 |
| Investor Presentation (August 2022) | Investor deck | 34 slides | Aug 1, 2022 |
| Technical Presentation (2021) | Technical | 15 slides | 2021 |
| Investor Presentation | Investor deck | 39 slides |
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares and pre-funded warrants Closed: US$275M raised · US$2.04 a share · Leerink Partners +5 Dealers: Leerink Partners (lead), Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital, Canaccord Genuity Buyers: BVF Partners L.P. (led the private placement; granted the right to designate two directors); Longitude Capital; Vivo Capital; TCGX; Spruce Street Capital; Venrock Healthcare Capital Partners; RA Capital Management; Perceptive Advisors; Driehaus Capital Management; Logos Capital; Catalio Capital Management Use of proceeds: Fund EB613 Phase 3 program through NDA submission, advance EB612 into the clinic with OPKO, and extend cash runway into 2030 | Aug 7, 2026 |
| Strategic investment of ordinary shares Closed: US$2.17 a share Buyers: OPKO (3,685,226 ordinary shares at $2.17 per share) Use of proceeds: To fund Entera's 40% share of costs of the oral GLP-1/glucagon program through Phase 1 | Mar 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$8.00 a unit on Jun 27, 2018.
- Price
- US$8.00 a unit
- Shares offered
- 1,400,000 ordinary shares
- Offering size
- US$11.2 million
- Underwriters' option
- Up to 210,000 more shares
- Listing
- ENTX on the Nasdaq Capital Market
- Underwriters
- Maxim Group LLC, Joseph Gunnar & Co. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 14, 2017 |
| Filed publicly | Nov 9, 2017 |
| Amended 7 times | Newest Jun 27, 2018 |
| Shares registered with an exchange | Jun 25, 2018 |
| Declared effective by the SEC | Jun 27, 2018 |
| Final prospectus, with the price | Jun 29, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 29, 2018 |
| EFFECT · Notice that a registration is effective | Jun 27, 2018 |
| F-1/A · Registration statement, amended | Jun 27, 2018 |
| CORRESP · Letter to the SEC | Jun 26, 2018 |
| CERT · Exchange's certificate of listing | Jun 26, 2018 |
| UPLOAD · Letter from the SEC | Jun 26, 2018 |
| CORRESP · Letter to the SEC | Jun 25, 2018 |
| CORRESP · Letter to the SEC | Jun 25, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 25, 2018 |
| CORRESP · Letter to the SEC | Jun 25, 2018 |
All 34 filings
Open IPO · From the cover of the final prospectus (424B4) filed Jun 29, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 42.0K | 181.0K | 0 | 134.0K | 571.0K | 365.0K |
| Cost of revenue | 42.0K | 172.0K | 0 | 101.0K | 373.0K | 300.0K |
| Gross profit | 0 | 9.00K | 0 | 33.0K | 198.0K | 65.0K |
| Research and development | 6.00M | 4.50M | 4.51M | 5.85M | 6.77M | 6.38M |
| Selling, general and administrative | 398.0K | 340.0K | ||||
| Operating income | -11.5M | -9.59M | -8.89M | -13.0M | -12.2M | -11.2M |
| Depreciation and amortization | 30.0K | 46.0K | 56.0K | 64.0K | 53.0K | 63.0K |
| EBITDA | -11.5M | -9.54M | -8.84M | -13.0M | -12.2M | -11.1M |
| Income before tax | -11.4M | -9.53M | -8.86M | -12.9M | -12.2M | -11.2M |
| Income tax | 0 | 14.0K | 29.0K | 137.0K | -59.0K | 20.0K |
| Net income | -11.4M | -9.54M | -8.89M | -13.1M | -12.2M | -11.2M |
| Earnings per share, basic | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 | 0.67 |
| Earnings per share, diluted | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 | 0.67 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 7.11M | 8.66M | 11.0M | 12.3M | 24.9M | 8.59M |
| Receivables | 0 | 126.0K | 0 | 246.0K | 183.0K | 255.0K |
| Current assets | 15.3M | 8.97M | 11.3M | 12.8M | 25.3M | 9.11M |
| Property, plant and equipment | 134.0K | 57.0K | 100.0K | 139.0K | 156.0K | 192.0K |
| Total assets | 16.0M | 9.39M | 11.8M | 13.1M | 26.0M | 9.72M |
| Accounts payable | 448.0K | 132.0K | 83.0K | 17.0K | 166.0K | 164.0K |
| Current liabilities | 2.20M | 1.18M | 1.09M | 1.34M | 3.16M | 1.84M |
| Total liabilities | 2.89M | 1.31M | 1.38M | 1.37M | 3.42M | 2.21M |
| Shareholders' equity | 13.1M | 8.08M | 10.4M | 11.8M | 22.6M | 7.51M |
| Shares outstanding | 46.2M | 38.8M | 35.5M | 28.8M | 28.8M | 21.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -7.37M | -6.82M | -7.31M | -12.5M | -9.06M | -10.6M |
| Capital spending | -107.0K | -3.00K | -17.0K | -47.0K | -17.0K | -53.0K |
| Free cash flow | -7.48M | -6.82M | -7.33M | -12.5M | -9.08M | -10.6M |
| Cash from investing | -107.0K | -3.00K | -17.0K | -102.0K | -17.0K | -53.0K |
| Cash from financing | 13.7M | 4.48M | 6.04M | 13.0K | 25.4M | 4.05M |
| Change in cash | 6.20M | -2.35M | -1.29M | -12.6M | 16.3M | -6.56M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 27, 2026 | Management or board change | SEC |
| DEF 14A · Proxy statement | Oct 14, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 6, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Sep 23, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 31, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Aug 28, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Aug 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| D | Aug 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 28, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 3, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jun 3, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 3, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 15, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | May 14, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | May 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| S-3 · Registration statement | May 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| 8-K · Current report | Apr 3, 2026 | Material contract | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 9, 2026 | Management or board change | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 8-K · Current report | Jul 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 18, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 9, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jun 6, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jun 5, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jun 5, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 5, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Jun 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 30, 2025 | Offer document | SEC |
| S-3 · Registration statement | May 30, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 23, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | May 20, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 20, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 14, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | May 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 2, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2025 | Results | SEC |
| 8-K · Current report | Mar 17, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jan 10, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 6, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Dec 20, 2024 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Nov 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 20, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 20, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 8-K · Current report | Aug 2, 2024 | Meeting outcome | SEC |
| 4/A · Change in ownership, amended | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 20, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jun 20, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 20, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Jun 7, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | May 29, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 8, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 8, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 8, 2024 | Results | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 424B3 · Prospectus | Feb 15, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Feb 14, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 2, 2024 | Current report | SEC |
| S-3 · Registration statement | Feb 2, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 3, 2024 | Current report | SEC |
| D | Jan 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 26, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 4 · Change in ownership | Sep 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 13, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Aug 15, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 15, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| PRER14A | Jul 28, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 30, 2023 | Current report | SEC |
| 25-NSE/A | Jun 29, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 27, 2023 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jun 23, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jun 7, 2023 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 2, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 5, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2023 | Results | SEC |
| 4 · Change in ownership | Apr 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2023 | Insider trade | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
This page holds 200 of 421 filings. Open Filings
Cap table
Built by 6ix from Entera Bio Ltd.’s releases · as of Aug 7, 2026
- Common shares
- 173,922,428
- Fully diluted
- 173,922,428
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 173,922,428 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 173,922,428 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Steve Rubin Other companies: Red Violet, Inc. (Director · Since at least Mar 26, 2018); Niagen Bioscience, Inc. (Director · Since at least Mar 27, 2017); Cocrystal Pharma, Inc. (Director · Since at least Mar 17, 2014); OPKO Health, Inc. (Executive VP-Administration, Director · Since at least Feb 9, 2007); VBI Vaccines Inc. (Director · Dec 31, 2016 – Jun 14, 2018 · Past); Fluent, Inc. (Director · Jan 11, 2010 – Apr 13, 2017 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Castle Brands Inc (Director · Jan 21, 2009 – Oct 8, 2019 · Past); Non-Invasive Monitoring Systems, Inc. (Director · Oct 30, 2008 – Feb 28, 2012 · Past); BioCardia, Inc. (Interim CEO and Interim CFO, Director · Sep 19, 2008 – Aug 11, 2016 · Past); Asensus Surgical Inc (Director · Sep 4, 2007 – Apr 23, 2013 · Past); Dreams Inc (Director · Jun 25, 2007 – Jun 19, 2009 · Past) | Director · Since at least Feb 1, 2026 |
| Geno Germano Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Precision BioSciences, Inc. (Director · Since at least Mar 10, 2020); Sage Therapeutics Inc (Director · Since at least Jun 6, 2018); Bioverativ Inc (Director · Jan 31, 2018 – Mar 8, 2018 · Past); The Medicines Company (Director · Nov 9, 2017 – Jan 6, 2020 · Past) | Chairman of the Board · Since at least Feb 4, 2026 |
| Miranda Toledano Other companies: Journey Medical Corporation (Director · Since at least Nov 16, 2021); NexGel, Inc (Director · Sep 9, 2021 – Aug 17, 2023 · Past); Compass Therapeutics, Inc. (Director · Jun 25, 2021 – Jun 25, 2021 · Past); Sorrento Therapeutics, Inc. (EVP-Corporate Development · Sep 16, 2016 – Sep 16, 2016 · Past) | Chief Executive Officer and Board Member · Since at least Jan 1, 2022 |
| Gerald Lieberman Other companies: Teva Pharmaceutical Industries Limited (Independent Director · Since at least Jan 1, 2018); Forest Laboratories Inc (Director · Aug 23, 2011 – Jul 1, 2014 · Past); AllianceBernstein Holding L.P. (President and COO, Director · Feb 3, 2006 – Jan 23, 2009 · Past) | Director · Since at least Jan 1, 2022 |
| Ron Mayron Other companies: IceCure Medical Ltd. (Chairman of the Board · Since at least Mar 18, 2026); Big Digital Energy, Inc. (Director · Nov 16, 2017 – Apr 4, 2018 · Past) | Director · Jan 1, 2022 – Jan 1, 2024 · Past |
| Roger Garceau Other companies: Protara Therapeutics, Inc. (Director · Since at least Jan 9, 2020) | Director · Jan 1, 2022 – Jan 1, 2024 · Past |
| Yonatan Malca Other companies: IceCure Medical Ltd. (Director · Since at least Mar 18, 2026) | Director · Since at least Jan 1, 2024 |
| Anke Hoppe | VP of Clinical Operations · Since at least Nov 5, 2026 |
| Arthur C Santora II | Chief Medical Officer · Jan 1, 2022 – Apr 24, 2023 · Past |
| Cherin Smith | SVP Clinical Operations · Since at least May 9, 2025 |
All 26 people
| Person | Seat |
|---|---|
| Dana-Garbeli Yaacov | Chief Financial Officer · Since at least Nov 5, 2026 |
| Dana Yaacov-Garbeli | Chief Financial Officer · Since at least Jan 1, 2022 |
| Gerald M. Ostrov | Board Member · Since at least Jan 2, 2023 |
| Gregory Burshtein | Chief Scientific Officer · Since at least May 28, 2024 |
| Haya Taitel | Board Member · Since at least Jun 4, 2023 |
| Hillel Galitzer | Chief Operating Officer · Since at least Mar 31, 2022 |
| Leslie Velka Gautam | Chief Business Officer · May 8, 2025 – May 8, 2025 · Past |
| Michal Kushnir | Head of Program Management · Since at least Nov 5, 2026 |
| Michele McDermott | SVP Medical Affairs · Since at least Nov 5, 2026 |
| Osnat Bar-Peled | Executive Director of IP · Since at least Nov 5, 2026 |
| Phillip Schwartz | President of R&D, Director · Jan 1, 2022 – Jan 20, 2022 · Past |
| Rachel B. Wagman | Chief Clinical Advisor · Since at least Oct 13, 2026 |
| Ramesh Ratan | U.S.based CFO · Jan 1, 2022 – Jan 19, 2022 · Past |
| Riccardo Paolo Camisasca | Chief Medical Officer · Since at least Aug 18, 2026 |
| Sean Ellis | Board Member · Since at least Jan 1, 2022 |
| Spiros Jamas | Chief Executive Officer · Jan 1, 2022 – Jan 18, 2022 · Past |
Log in to ask 6ix AI your own questions about Entera Bio Ltd.